他莫昔芬改变声带损伤中的TGF-β1/Smad信号传导
本研究通过体外和体内实验探讨他莫昔芬(TAM)是否通过改变转化生长因子β1(TGF-β1)信号通路抑制声带纤维化。体外实验中,TAM(10⁻⁸或10⁻⁹ M)联合TGF-β1(10 ng/ml)可显著增加Smad7和Has3表达,降低Col1a1和Acta2表达;体内大鼠实验显示TAM(50 mg/kg/day)较假手术组显著增加固有层面积和透明质酸浓度,减少胶原沉积。结论认为TAM通过调控TGF-β1/Smad信号通路具有抗纤维化潜力。
要点
- 体外TAM联合TGF-β1可上调Smad7和Has3、下调Col1a1和Acta2表达。
- 体内口服TAM 50 mg/kg/day可增加大鼠声带固有层面积和透明质酸浓度。
- TAM可减少大鼠声带损伤后的胶原沉积。
核心结论
- TAM通过调控声带损伤中的TGF-β1/Smad信号通路具有抗纤维化潜力,为声带纤维化创新治疗提供基础数据。
研究设计与样本
- 体外:声带成纤维细胞接受TAM(10⁻⁸或10⁻⁹ M)±TGF-β1(10 ng/ml)处理以定量细胞增殖,并用实时定量聚合酶链反应检测纤维化相关基因。
- 体内:大鼠声带单侧损伤,自损伤前第5天至损伤后第7天经口灌胃给予TAM,随机分为0 mg/kg/day(假手术)组和50 mg/kg/day(TAM)组,第56天检查组织学变化以评估组织结构。
主要发现
- TAM(10⁻⁸ M)不影响Smad3、Smad7、Acta2或细胞外基质代谢相关基因。
- TAM(10⁻⁸或10⁻⁹ M)+TGF-β1较单用TGF-β1显著增加Smad7和Has3表达,并降低Col1a1和Acta2表达。
- 体内TAM较假手术组显著增加固有层面积和透明质酸浓度,并减少胶原沉积。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Effective treatments for vocal fold fibrosis remain elusive. Tamoxifen (TAM) is a selective estrogen receptor modulator and was recently reported to have antifibrotic actions. We hypothesized that TAM inhibits vocal fold fibrosis via altered transforming growth factor beta 1 (TGF-β1) signaling. Both in vitro and in vivo approaches were employed to address this hypothesis. METHODS: In vitro, vocal fold fibroblasts were treated with TAM (10-8 or 10-9 M) ± TGF-β1 (10 ng/ml) to quantify cell proliferation. The effects of TAM on genes related to fibrosis were quantified via quantitative real-time polymerase chain reaction. In vivo, rat vocal folds were unilaterally injured, and TAM was administered by oral gavage from pre-injury day 5 to post-injury day 7. The rats were randomized into two groups: 0 mg/kg/day (sham) and 50 mg/kg/day (TAM). Histological changes were examined on day 56 to assess tissue architecture. RESULTS: TAM (10-8 M) did not affect Smad3, Smad7, Acta2, or genes related to extracellular matrix metabolism. TAM (10-8 or 10-9 M) + TGF-β1, however, significantly increased Smad7 and Has3 expression and decreased Col1a1 and Acta2 expression compared to TGF-β1 alone. In vivo, TAM significantly increased lamina propria area, hyaluronic acid concentration, and reduced collagen deposition compared to sham treatment. CONCLUSIONS: TAM has antifibrotic potential via the regulation of TGF-β1/Smad signaling in vocal fold injury. These findings provide foundational data to develop innovative therapeutic options for vocal fold fibrosis. LEVEL OF EVIDENCE: NA Laryngoscope, 133:2248-2254, 2023.
引用
- Matsushita H, Mukudai S, Ozawa S, et al. Tamoxifen Alters TGF-β1/Smad Signaling in Vocal Fold Injury. Laryngoscope. 2022. PMID: 36250536. doi:10.1002/lary.30448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。